Tag Archives: Globally

Hot Investor Mandate 4: Germany-Based CVC with a Global Presence Invests in Innovative Medical Technologies Globally, Including Imaging & PoC and In Vitro Diagnostics

7 Jun

A corporate venture firm is headquartered in Munich, Germany, with additional offices worldwide. The fund invests in medical technology companies that are strategically relevant to the corporate’s interests. Investments in equity rounds range from $1-5 million and are made worldwide.

The firm’s primary focuses within healthcare are medical imaging (including both equipment and software) and diagnostics (particularly point of care diagnostics and molecular diagnostics). In these sectors, the firm focuses on products used in a hospital setting. The firm also invests in digital health solutions that add value to imaging and diagnostics, such as data-as-a-service products. The firm is potentially interested in medical robotics. The firm will invest in any medical indication area, and only invests in companies that have attained proof of concept data for their product, with a preference for companies that have a product on the market that can demonstrate traction and revenue.

The firm generally does not attach strategic rights to an investment other than the right to be informed if the company is seeking a buyer. The firm requires a board seat or a board observer in each portfolio company.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 4: Hong Kong-based Family Office Seeking Small Molecule Therapeutics, Devices, Diagnostics, and Healthcare IT Globally

10 May

A wholly-owned venture arm of a Hong-Kong based family is focused on making early stage life science investments across sectors such as new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT and etc. The firm is managed by a team of investment professionals who are entrepreneurial, have deep scientific and industry knowledge and are effective in the environment in which they operate.

The firm seeks to invest in new therapeutics, diagnostics, medical devices, medical/healthcare services, healthcare IT etc. For therapeutics, the firm seeks novel small molecule and biologics and is agnostic in terms of indication. However, indications that address a large market in China are of interest. The firm looks for early stage assets in pre-clinical and phase I of clinical trials. However, the firm will not rule out assets in phase II. For devices, the firm is opportunistic in terms of the class of device.

The firm seeks an active role in its portfolio companies and generally obtain a seat on the board.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

Hot Investor Mandate 3: Technology Firm Establishes New Venture Fund for Investing in Early-Stage Digital Health Companies Globally

5 Apr

An operating group of a global public technology firm with an $18B market cap. The group began its venture portfolio in 2018 with investments in B-to-B software companies targeted at specific vertical markets such as healthcare. The fund invests $0.5M – 1M per company and is seeking companies raising seed to Series B rounds. The company is seeking 5 – 10 new investments to build their initial portfolio. The company prefers companies based in Canada, though as the parent firm is located in the US, UK, EU, and AU, the fund is open to invest globally.

The company is seeking healthcare IT, and they are particularly investing in technologies with a software component. The firm prefers commercial-stage companies, though is open to looking at clinical-stage companies as well. The company is indication agnostic.

The company will help companies fill management team positions, if necessary. The company prefers companies that are generating $100K – 3M in annual revenue.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com.

%d bloggers like this: